Retinal ganglion cell (RGC) death is implicated in a number of eye disorders that are broadly defined as optic neuropathies.[@bib1] Glaucoma, the most common form of optic neuropathy, is characterized by a progressive loss of RGCs and their axons, and, if left untreated, leads to irreversible vision loss.[@bib2] Currently, there are no effective treatments for degenerative retinal diseases resulting from RGC loss. The only clinically proven treatment of glaucoma is a pharmacological or surgical reduction of intraocular pressure, one of the main risk factors in this devastating eye disease.[@bib3] However, the reduction of intraocular pressure is not always sufficient to stop RGC death and axon damage. There are growing efforts to develop strategies for effective reduction of RGC death such as suppression of pro-apoptotic signaling, modulation of the inflammatory response, and neurotrophic factor delivery.[@bib4]^--^[@bib7]

While lower vertebrates like zebrafish can functionally regenerate injured central nervous system (CNS) axons after injury such as optic nerve crush (ONC),[@bib8]^--^[@bib10] CNS axon regeneration fails in mammals and adult birds. Adult RGCs are part of the CNS and are thus incapable of regenerating their axons beyond the injury site.[@bib11] As a result, many of the axotomized RGCs die. This inability of CNS axons to regenerate is mainly caused by the cell\'s intrinsic growth capacity failing to activate after injury[@bib12] as well as the presence of extrinsic inhibitory factors.[@bib13]^--^[@bib15] Nevertheless, some RGCs survive the injury with αRGCs showing increased survival rate.[@bib16]

Several proteins of different functional classes have been identified to promote survival of RGCs and/or regeneration of their axons.[@bib17]^--^[@bib24] Some of them are transcription factors, such as Sox11[@bib25] and a number of the Kruppel-like factor family.[@bib26] Activating transcription factor 3 (ATF3), also known as LRF-1, LRG-21, CRG-5, and TI-241, belongs to the ATF/cyclic AMP responsive element binding family of proteins characterized by a basic region leucine zipper motif.[@bib27] *ATF3* is described as stress inducible and an adaptive response gene.[@bib28]^,^[@bib29] *ATF3* is not expressed in most healthy intact neurons, however expression is induced after axonal injury.[@bib30] In the peripheral nervous system, increased and retained expression of ATF3 has been associated with both neuroprotective and regenerative effects.[@bib31]^--^[@bib33] It has been demonstrated in several species, including mice[@bib22]^,^[@bib34]^,^[@bib35], rats,[@bib36]^,^[@bib37] and zebrafish,[@bib38] that the level of *Atf3* gene expression is low in RGCs but is upregulated after ONC.

In this study, we investigated the role of ATF3 in RGC survival and regeneration of their axon after ONC in mice. We demonstrated that overexpression of ATF3 in RGCs by intravitreal injection of recombinant adenovirus-associated virus (rAAV), delivered before the ONC, promoted survival of RGCs and partially preserved their function 2 weeks after ONC. In addition, overexpression of ATF3 together with downregulation of phosphatase and tensin homolog (PTEN) promoted RGC axon regeneration after ONC. These results identify ATF3 as a potential agent for the treatment of traumatic optic neuropathies.

Materials and Methods {#sec2}
=====================

Animals {#sec2-1}
-------

Adult C57BL/6 mice were obtained from the Jackson Laboratory. Mice were 35 days old at the time of rAAV2 injections and 49 days old at the time of ONC. Animals were kept on a standard 12/12 hours light/dark cycle and all assessments of visual functions were conducted in the first 8 hours of the light phase. Adult floxed *PTEN*^f/f^ mice were maintained as previously reported.[@bib39] Mice were maintained and treated in accordance with guidelines set forth by the National Eye Institute Committee on the Use and Care of Animals and the Association for Research in Vision and Ophthalmology\'s Statement for the Use of Animals in Ophthalmic and Visual Research.

Plasmid and rAAV Production {#sec2-2}
---------------------------

Plasmid preparation and rAAV production were performed as previously described.[@bib40] Plasmids pAAVrep2cap2, pAAV-CMV-Cre, pAAV-CMV-LacZ, and pAAV-CMV-PLAP (placental alkaline phosphatase) have been previously described.[@bib39] Plasmid pAAV-CMV-ATF3 was generated from previously described plasmid pAAV2-CMV-Otx2 by subcloning and replacing the *OTX2* sequence with the *ATF3* sequence cloned from plasmid pCMV-SPORT6-mATF3 (Dharmacon, Lafayette, CO). The pAAV2 vectors with transgene cassettes encoding PLAP, GFP, Cre, or ATF3 under control of the CMV promoter were packaged into the AAV2 capsid as previously described.[@bib41] Briefly, HEK 293T cells were triple transfected with pHelper, pAAVrep2cap2, and pAAV2-CMV-(Transgene) plasmids using polyethylenimine (Sigma Aldrich, Allentown, PA ). Cells were harvested 48 hours after transfection. Viral particles were purified by centrifugation through iodixanol (Sigma Aldrich) gradient (15%, 25%, 40%, and 60%). The 40% fraction containing the rAAV viral particles was collected and passed through the column for desalting. Viral particles were suspended and stored in 1× phosphate-buffered saline (PBS), 0.001% Pluronic (Life Technologies, Foster City, CA). Titers (viral genomes per milliliter) were determined by real-time polymerase chain reaction using primers targeting the CMV promoter: 5′-ATGCGGTTTTGGCAGTACAT-3′ and 5′-GTCAATGGGGTGGAGACTTG-3′.

Gene Transfer and Surgical Methods {#sec2-3}
----------------------------------

For intravitreal injections and ONC, mice were anesthetized with a single intraperitoneal injection of ketamine/xylazine (100 and 10 mg/kg, respectively). An ophthalmic solution with phenylephrine hydrochloride (Paragon, Portland, OR), tropicamide (Akorn, Lake Forest, IL), and proparacaine hydrochloride (Sandoz, Princeton, NJ) was applied to the cornea. rAAV intravitreal injections were conducted using a 34-gauge Hamilton needle and a Hamilton syringe (Hamilton Company, Reno, NV). Approximately 3 μL (3 × 10^10^ rAAV2 viral particles) were injected into the vitreous chamber using UltraMicroPump (UMP3, World Precision Instruments, Sarasota, FL). ONC was performed 2 weeks after virus injection. The optic nerve was exposed intraorbitally and crushed with self-closing Dumont Tweezers \#5 (World Precision Instruments) for 3 seconds approximately 0.5 mm behind the eyeball. Care was taken not to damage the underlying retinal artery. One microliter of Alexa Fluor 594-conjugated cholera toxin subunit B (CTB) (ThermoFisher Scientific, Marietta, OH) was injected intravitreally 2 to 3 days before euthanasia to label regenerating axons. Eye ointment containing neomycin (Akorn, Somerset, NJ) was applied to protect the cornea after CTB injection. Animals received buprenorphine as an analgesic after the operation.

Histology {#sec2-4}
---------

Enucleated* *eyes and surgically removed optic nerve segments were fixed in 4% paraformaldehyde in PBS for 20 minutes and then washed three times for 20 minutes each in PBS. To prepare frozen sections (14 µm), tissues were immersed in 30% sucrose for 2 days and then embedded in OCT before sectioning using a cryostat. For immunofluorescent staining, sections were washed in PBS, incubated with 0.5% Triton X-100 for 20 minutes and then washed again with PBS for 10 minutes. Sections were incubated in 0.5% bovine serum albumin, 15% normal goat serum, and 0.3% Tween-20 for 10 minutes followed by the incubation with primary antibodies in a blocking buffer (0.5% BSA and 0.3% Tween-20 in PBS) at 4°C overnight, and then with secondary antibodies in a blocking buffer at room temperature for 2 hours. Whole-mount retinas were incubated with 0.5% Triton X-100 at -80°C for 10 minutes. Blocking was performed using 2% BSA and 2% Triton X-100 at 4° C for 4 hours followed by the incubation with primary antibodies in a blocking buffer overnight at 4°C and secondary antibodies in a blocking buffer for 2 hours at room temperature. After incubation with antibodies, frozen sections and whole-mount retinas were extensively washed with PBS at room temperature and mounted in prolong gold anti-fade mount (ThermoFisher Scientific). The following primary and secondary antibodies were used for staining: guinea pig anti-RBPMS (1:500, Millipore SIGMA, Burlington, MA), mouse anti-ATF3 (1:50, Abcam, Cambridge, MA), rabbit anti-phospho-S6 ribosomal protein (Ser235/236) (1:100, Cell Signaling, Danvers, MA) and goat anti-osteopontin (1:1,000, R&D Systems Inc., Minneapolis, MN), goat anti-guinea pig IgG (1:500, ThermoFisher Scientific), goat anti-mouse IgG (1:500, ThermoFisher Scientific), and goat anti-rabbit IgG (1:500, ThermoFisher Scientific).

Imaging and Quantification {#sec2-5}
--------------------------

Fluorescently stained cells were analyzed using a Zeiss LSM 700 confocal laser-scanning microscope (Carl Zeiss Inc, Thornwood, NY). Images were analyzed and organized using Fiji (National Institutes of Health, Bethesda, MD) and Photoshop (Adobe, San Jose, CA). Investigators were blinded to the identity of the samples at the time of image analysis. For RGC quantification (RGCs/mm^2^) in whole-mount retina samples, 12 fields (0.3 × 0.3 mm) positioned in the center, middle part, and periphery of the RGC layer were selected. Five retinas from five mice were used for the calculation of the mean number of RGCs/mm^2^ for rAAV-injected samples and three retinas from three mice were used for a control intact group. Regenerating RGC axons in injured optic nerves distal to the crush site were quantified as described.[@bib39]^,^[@bib42] Harvested optic nerves were fixed in 4% paraformaldehyde, treated with 30% sucrose, and then frozen in OCT and stored at -80° degrees until they were sectioned. Ten-micrometer longitudinal sections of optic nerves were used to visualize CTB stained axons. The number of CTB-labeled axons was estimated by counting the number of CTB-labeled fibers extending different distances from the crush site. The cross-sectional width of the optic nerve was measured at the point at which the counts were taken and was used to calculate the number of axons per millimeter of nerve width. The number of axons per millimeter was then averaged over all sections. Σad, the total number of axons extending distance, d, in a nerve having a radius, r, was estimated by summing over all sections: Σad = πr^2^ × \[average number of axons/mm width\]/section thickness.

Electroretinography {#sec2-6}
-------------------

An electroretinography (ERG) response was recorded using the Espion Ganzfeld full field system (Diagnosys LLC, Lowell, MA) before ONC (baseline) and 7 days post-ONC (dpc). Mice were dark adapted for 12 hours overnight and prepared for ERG recording under dim red light (\>630 nm). Anesthesia was induced with intraperitoneal injection of ketamine/xylazine and eyes were dilated as described previously. A scotopic flash ERG response was recorded from 10^−7^ to 0.005 mcd/s units with respect to a standard flash in half log-unit steps. ERG traces were analyzed using in-built Espion software and the peak amplitude (with respect to baseline) was used as a measure of visual function. ERGs traces at the light intensity of 1 × 10^−5^ mcd/s were chosen for analysis as they gave a clean, unambiguous positive scotopic threshold response (pSTR) with a mean latency of 100 ms. The response of photoreceptors was assessed at 0.005 mcd/s.

Statistical Analysis {#sec2-7}
--------------------

All statistic tests were performed using SPSS 17.0 (IBM SPSS, Inc., Chicago, IL), and data presented as mean ± standard error of the mean (SEM) with graphs constructed using GraphPad Prism (La Jolla, CA). A *t*-test or one-way or two-way ANOVA with Tukey or Sidak correction were used for multiple comparisons, as detailed in the corresponding figure legends. Statistical differences were considered significant at *P* values \< 0.05.

Results {#sec3}
=======

Elevation of ATF3 Level in αRGCs After Optic Nerve Crush {#sec3-1}
--------------------------------------------------------

There are more than 40 different RGC types differing by their morphology, physiological properties, gene expression patterns, and reaction to different insults in mice.[@bib43]^--^[@bib45] It is not known whether upregulation of ATF3 levels after ONC occurs in all RGC types or is associated with a particular RGC type(s). First, we checked whether ATF3 is upregulated in osteopontin^+^ (OPN^+^) αRGCs after ONC (in comparison to the total RBPMS^+^ RGC population). OPN is a marker for αRGCs,[@bib16] which survive much better than non-αRGCs after ONC[@bib16]^,^[@bib39] and play an important role in visual processing. RBPMS is consistently expressed in all RGC types before and after optic nerve injury[@bib46]^,^[@bib47] Uninjured retinal samples showed very low levels of ATF3 labeling, whereas the levels of ATF3 staining in RGCs was dramatically increased after ONC ([Fig. 1](#fig1){ref-type="fig"}A). Consistent with previous reports,[@bib16]^,^[@bib39] about 36% of RGCs survived over the first 10 dpc ([Fig. 1](#fig1){ref-type="fig"}A). αRGCs survived much better than non-αRGCs (72.6% ± 10.4% vs. 32.3 ± 1.7%, respectively, *P* \< 0.001, unpaired *t*-test) ([Figs. 1](#fig1){ref-type="fig"}A, C). As a result, the fraction of αRGCs raised from 8% in control uninjured retina to 22% in retina by 10 dpc ([Fig. 1](#fig1){ref-type="fig"}D). Most of the surviving OPN^+^ αRGCs were ATF3^+^ (81.7 ± 15.6%), whereas only 32.3 ± 3.4% of surviving non-αRGCs were ATF3^+^ ([Figs. 1](#fig1){ref-type="fig"}B, E).

![ONC leads to preferential elevation of ATF3 level in αRGC. (**A**) Transverse sections of intact uninjured retina and retina 10 dpc were stained for OPN (red), ATF3 (green) and RBPMS (gray scale). (**B**) Merged images for ATF3/RBPMS and ATF3/OPN staining at 10 dpc. (**C**) Percent of αRGCs and non-αRGCs that survived at 10 dpc. (**D**) Fraction of all RGCs comprised by αRGCs and non-αRGCs in intact retina and at 10 dpc. (**E**) Percent of ATF3 positive αRGCs and non-αRGCs at 10 dpc. Six and five biological replicates were used for 10 dpc and control, non-crushed eyes groups, respectively. Data are shown as mean ± SEM. Unpaired *t*-test was used for statistical analysis; *P* values are shown above corresponding columns.](iovs-61-2-31-f001){#fig1}

ATF3 Overexpression Promotes RGC Survival Following ONC {#sec3-2}
-------------------------------------------------------

Since ATF3 is preferentially upregulated in αRGCs after ONC, we tested whether overexpression of ATF3 in different RGC types may improve their survival. Our preliminary experiments demonstrated that rAAV2 expressing EGFP (rAAV-EGFP) efficiently transduced RGCs. EGFP fluorescence was detected in more than 80% of RGCs 1 week after intravitreal viral injection in the conditions described in the Materials and Methods (data not shown). rAAV2s expressing ATF3 or PLAP were injected into the vitreous 14 days before ONC ([Figs. 2](#fig2){ref-type="fig"}A-D). rAAV-PLAP was used as a negative control because it has been previously demonstrated that overexpression of PLAP does not affect retinal morphology and RGC axon regeneration.[@bib48] The number of RBPMS^+^ RGCs in the intact retina was 4087 ± 319 cells/mm^2^. Overexpression of ATF3 led to a statistically significant increase in the number of surviving RGCs over PLAP-injected samples (1259 ± 127 cells/mm^2^ vs. 617 ± 53 cells/mm^2^, respectively; *P* = 0.001) after ONC ([Figs. 2](#fig2){ref-type="fig"}C, D). Compared with intact retina, 30.8 ± 3.1% RGCs survived after ATF3 overexpression, whereas only 15.1 ± 1.3% RGCs survived after PLAP overexpression (*P* = 0.003) ([Fig. 2](#fig2){ref-type="fig"}E). However, a single rAAV-ATF3 injection was not sufficient to provide RGC neuroprotection 6 weeks after ONC ([Supplementary Fig. S1](#IOVS-61-2-31_s001){ref-type="supplementary-material"}).

![Effects of rAAV-ATF3 overexpression on RGC survival. (**A**) Timeline of in vivo study. (**B**) Scheme of RGC counting; squares represent counting fields. (**C**) Representative images of regions within whole-mount retinas for different groups. Right image (intact) corresponds to noninjected/non-ONC retina. (**D**) Quantification of RGCs for different groups. (**E**) Percentage of surviving RGCs 14 dpc normalized to intact retinas (100%). Eight biological replicates were used for rAAV-ATF3 and rAAV-PLAP groups, three biological replicates were used for intact retina. Each biological replicate represents the average of 12 different fields in the retina. Data are shown as mean ± SEM. Two-way ANOVA with a Tukey post hoc test, was used for **D**, and unpaired *t*-test comparison for **E**. *P* values are shown above corresponding the graph.](iovs-61-2-31-f002){#fig2}

To test whether overexpression of ATF3 affects RGC axon regeneration, optic nerves of rAAV-ATF3 or rAAV-PLAP injected eyes were analyzed 10 dpc. Overexpression of ATF3 increased the number of regenerating axons at 0.2 mm and 0.5 mm distances from the ONC site compared with PLAP overexpression ([Figs. 3](#fig3){ref-type="fig"}A, B), but the observed differences were not statistically significant ([Figs. 3](#fig3){ref-type="fig"}A, B).

![Effects of ATF3 overexpression on RGC axon regeneration after ONC. (**A**) Representative images of optic nerve sections from rAAV-ATF3- and rAAV-PLAP-treated eyes 10 dpc. CTB-labeled regenerating axons were visualized as described in Materials and Methods, crush sites are indicated by asterisks. (**B**) Quantification of regenerating axons as in **A**. N = 9 and 8 for ATF- and PLAP-injected samples, respectively. Data are shown as mean ± SEM. Two-way ANOVA test was used for **B**.](iovs-61-2-31-f003){#fig3}

ATF3 Overexpression Partially Preserves RGC Function {#sec3-3}
----------------------------------------------------

Changes in the functional properties of RGCs after ONC were tested by measuring the pSTR because the amplitude of the pSTR is a measure of RGC functions.[@bib47] pSTR recordings were performed 7 dpc ([Fig. 4](#fig4){ref-type="fig"}). Twelve different biological replicates were used for each group. In the intact retina, the pSTR amplitude recorded at a low flash intensity (10^−5^ mcd/s) was 20.1 ± 2.2 µV ([Fig. 4](#fig4){ref-type="fig"}B). ONC in the rAAV-PLAP injected control group led to a significant decrease in the pSTR amplitude compared with intact retina (3.95 ± 0.85 μV, *P* \< 0.0001), while overexpression of ATF3 preserved the pSTR amplitude (16.3 ± 2.0 μV) ([Figs. 4](#fig4){ref-type="fig"}A, B). ONC in combination with injections of viral constructs did not lead to statistically significant changes in the scotopic photoreceptor response (a-wave) recorded at a higher flash intensity (0.005 mcd/s) 7 dpc ([Figs. 4](#fig4){ref-type="fig"}A, C), indicating that photoreceptor functions were not affected.

![Effects of ATF3 overexpression on the pSTR and scotopic responses 7 dpc. (**A**) Representative traces of the observable pSTR at different light intensities. \*The time of flash-light stimulation. The pSTR was measured at the position marked by dash line. (**B**) Mean pSTR and **(C**) scotopic amplitudes in different experimental groups. Intact group corresponds to undamaged samples. Twelve different biological replicated were used for each group. *P* value are shown above the graph; ns, not statistically significant. Data are shown as mean ± SEM. One-way ANOVA test was used.](iovs-61-2-31-f004){#fig4}

ATF3 Overexpression Works Synergistically with PTEN Knockdown to Induce RGC Axon Regeneration {#sec3-4}
---------------------------------------------------------------------------------------------

Previous studies demonstrated that deletion of *PTEN*, a negative regulator of the mTOR pathway, in RGCs promotes the survival of αRGCs and regeneration of their axons after ONC.[@bib16]^,^[@bib39] To test whether ATF3, like some other factors,[@bib25] may act synergistically with activation of the mTOR pathway by downregulation of PTEN, we used *PTEN*^f/f^ mice.[@bib49] Activation of the mTOR pathway was achieved by downregulation of PTEN using intravitreal injection of rAAV-Cre as previously described.[@bib39] rAAV-Cre was injected into vitreous together with rAAV-ATF3 or rAAV-PLAP. ONC was performed 14 days later and retina/optic nerve samples were analyzed 14 dpc. Six different biological replicates were used for a PLAP/PTEN control group and four for an ATF3/PTEN group. Although ATF3 improved survival of RGCs at 14 dpc in wild-type mice ([Fig. 2](#fig2){ref-type="fig"}), no significant differences were detected between rAAV-ATF3 and control rAAV-PLAP when combined with *PTEN* deletion (652 ± 33 and 699 ± 12 RGCs/mm^2^, respectively), suggesting the neuroprotective effects between the two treatment conditions are not synergistic ([Figs. 5](#fig5){ref-type="fig"}A, B). At the same time, *PTEN* deletion combined with ATF3 overexpression produced more regenerating axons than *PTEN* deletion combined with PLAP overexpression at 0.2 mm distance from the ONC site (1156 ± 117 and 628 ± 114 axons, respectively, *P* \< 0.0001). No statistically significant differences between these two conditions were observed at longer distances (\>0.2 mm) from the ONC site ([Figs. 5](#fig5){ref-type="fig"}C, D).

![Effects of ATF3 overexpression and *PTEN* deletion on RGC survival and axon regeneration after ONC. (**A**) Representative images of areas of whole-mount retinas stained with antibodies against RBPMS at 14 dpc. (**B**) Quantification of RGCs. The number of RGCs/mm^2^ is shown. (**C**) Representative images of optic nerve sections at 14 dpc. CTB-labeled regenerating axons were visualized as described in Materials and Methods; crush sites are indicated with asterisks. (**D**) Quantification of regenerating axons as in **C**. Six and four different biological replicates were used for PLAP/PTEN control group and ATF3/PTEN, respectively. Data are shown as mean ± SEM. Unpaired *t*-test was used for **B**; ns, not statistically significant. Two-way ANOVA test was used for **D**. No statistically significant differences were detected at a distance \>0.2 mm.](iovs-61-2-31-f005){#fig5}

mTOR Activation Inhibits Endogenous ATF3 Expression After ONC {#sec3-5}
-------------------------------------------------------------

A phosphorylated form (Ser235/236) of ribosome protein S6 (pS6) is a reliable marker of mTOR activity.[@bib39]^,^[@bib50] It has been shown that the level of pS6 is reduced in RGCs of wild-type retina after ONC while PTEN suppression restores pS6 level.[@bib16]^,^[@bib39] The pS6 level is more dramatically increased in αRGCs in comparison with non-αRGCs when *PTEN* deletion was combined with ONC.[@bib16] Since ATF3 level is increased in αRGCs after ONC ([Fig. 1](#fig1){ref-type="fig"}), we tested whether mTOR activity and ATF3 expression were correlated at the molecular level. The activation of mTOR signaling in non-injured retinas by *PTEN* deletion (*PTEN*^−/−^) did not induce ATF3 expression ([Fig. 6](#fig6){ref-type="fig"}A). As expected, ONC induced expression of ATF3 in the RGCs of control *PTEN*^+/+^ mice ([Fig. 6](#fig6){ref-type="fig"}A). However, upregulation of ATF3 expression in RGCs after ONC was suppressed when *PTEN* was deleted ([Fig. 6](#fig6){ref-type="fig"}A), suggesting that ONC-induced expression of ATF3 is PTEN-dependent. At 3 dpc, a significant decrease in the percentage of ATF3-positive RGCs in *PTEN*^−/−^ was observed compared with *PTEN*^+/+^ retinas, (1.56% ± 0.03 and 57.7% ± 1.5, respectively, *P* = 0.0007) ([Fig. 6](#fig6){ref-type="fig"}C). Similarly, a significant decrease in the percentage of ATF3 positive αRGCs in *PTEN*^−/−^ was found compared to *PTEN*^+/+^ samples (9.23% ± 2.05 and 80.13% ± 9.23, respectively, *P* = 0.0004) ([Fig. 6](#fig6){ref-type="fig"}D).

![mTOR signaling inhibits endogenous expression of ATF3. (**A**) Transverse sections of control retina (intact) and retina 3 dpc with or without *PTEN* deletion. Sections were stained with indicated antibodies. (**B**) Representative images of whole-mount, nonoptic nerve crush retinas immunohistochemically stained for ATF3, RBPMS, and pS6 7 days after intravitreal injections of corresponding rAAV viruses. (**C**) Percentage of ATF3 positive RGCs in *PTEN*^+/+^ and *PTEN*^−/−^ retinas at 3 dpc. (**D**) Percentage of ATF3 positive αRGCs in *PTEN*^+/+^ and *PTEN*^−/−^ retinas at 3 dpc. Data are shown as mean ± SEM. Unpaired *t*-test was used for **C** and **D**. N = 3 for each group in **A-D.**](iovs-61-2-31-f006){#fig6}

Next, we tested whether overexpression of ATF3 may modulate the mTOR pathway. In a noninjured retina, overexpression of ATF3 by intravitreal injection of rAAV-ATF3 had no detectable effect at the level of pS6 expression compared to control retina from eyes injected with rAAV2-PLAP 1 week after viral injection ([Fig. 6](#fig6){ref-type="fig"}B).

Discussion {#sec4}
==========

Only a few RGCs survive after ONC and even fewer can extend their axons through the injury site,[@bib51] with different subtypes showing dramatic differences in the survival rate and ability to regenerate their axons.[@bib16] αRGCs have been previously shown to survive better than many other RGC types and account for nearly all the regeneration seen following downregulation of PTEN and subsequent activation of the mTOR pathway.[@bib16] Furthermore, αRGCs preferentially express OPN and receptors for insulin-like growth factor 1. Overexpression of these proteins promotes regeneration of αRGC axons.[@bib16] Other factors and signaling pathways might be also involved in RGC neuroprotection and stimulation of axon regeneration.[@bib10] One of these factors is the transcription factor ATF3, known to be inducible by stress and axonal injury in both the peripheral nervous system and CNS.[@bib27]^,^[@bib30] In the adult intact retina, expression of ATF3 is not detected in RGCs; however, a fraction of RGCs were shown to upregulate ATF3 after ONC.[@bib22] In this paper, we demonstrated that more than 80% of αRGCs surviving after ONC were positive for ATF3 expression while only 30% of non-αRGCs were ATF3^+^ ([Fig. 1](#fig1){ref-type="fig"}D). Although we did not analyze the nature of surviving ATF3^+^ non-αRGCs, we assumed that some of these cells could be melanopsin expressing M1-RGCs because these cells, similar to αRGCs, preferentially survive after ONC.[@bib16] Indeed, it has been recently demonstrated that, similar to αRGCs, the level of *Atf3* gene expression is very low in melanopsin expressing RGCs in a control undamaged mouse retina and is dramatically upregulated in these cells after ONC.[@bib52] We showed that overexpression of ATF3 by intravitreal injection of rAAV-ATF3 before ONC promoted survival of RGCs for at least 2 weeks ([Fig. 2](#fig2){ref-type="fig"}). The neuroprotective effect of ATF3 overexpression was similar to that of neuritin, a known RGC neuroprotective factor.[@bib7]^,^[@bib53] However, a single rAAV-ATF3 injection was not sufficient for RGC neuroprotection over 6 weeks. This indicates that ATF3 effects on injured RGCs may be transient or that multiple rAAV-ATF3 injections are needed, similar to a rat glaucoma model where RGC neuroprotection by intravitreal injections of small extracellular vesicles required monthly injections while a single injection was not effective over 2 months.[@bib54] Stimulation of RGC axon regeneration by ATF3 after ONC was minor with no statistically significant differences between control and ATF3 samples detected ([Fig. 3](#fig3){ref-type="fig"}). Although abilities of a particular RGC type to survive and regenerate axons after ONC very often correlate, this is not always the case. For example, melanopsin-expressing M1-RGCs and αRGCs survive preferentially after ONC but only the αRGCs, not M1-RGCs, regenerate their axons.[@bib16] Overexpression of Sox11 kills αRGCs yet promotes the regeneration of non-αRGC axons after ONC.[@bib25] It appears that overexpression of ATF3 is not sufficient to activate a set of genes essential for RGC axon growth.

Overexpression of ATF3 also provided preservation of RGC functions as judged by measuring the pSTR amplitude ([Fig. 4](#fig4){ref-type="fig"}). Surprisingly, the preservation of RGC functions was more pronounced than the preservation of RGC numbers. It has been previously shown that ATF3 not only protects hippocampal neurons against neuronal death but also enhances their ability to recover synaptic connections and reestablish functional networks after excitotoxic insults.[@bib55] It is thus feasible that surviving RGCs overexpressing ATF3 may have enhanced ability to reestablish synaptic connections with neurons in the inner nuclear layer, counteracting the cell loss and preserving visual function and RGCs response to light stimuli. Another possibility is that overexpression of ATF3 may enhance the excitation of individual RGCs in response to ONC. It has been reported that sodium channel NaV1.6 was transiently increased in RGC axons in mice 2 weeks after intraocular pressure elevation, leading to enhanced axon firing in response to light stimulus.[@bib56] Further studies are necessary to find out whether any of these possibilities may contribute to the preservation of RGC functions after ATF overexpression.

It is now well established that deletion of *PTEN*, a negative regulator of the mTOR pathway, in RGCs promotes their survival and the regeneration of αRGC axons after ONC.[@bib16]^,^[@bib39]^,^[@bib57] *PTEN* deletion in combination with overexpression of Sox11 may further enhance axon regeneration from non-αRGCs.[@bib25] At the same time, overexpression of Sox11 enhanced αRGC death after ONC and, as a result of this, overexpression of Sox11 in combination with *PTEN* deletion decreased the survival of total population of RGCs.[@bib25] Unlike Sox11, overexpression of ATF3 in combination with *PTEN* deletion did not decrease the survival of total population of RGCs, but similar to Sox11, enhanced axon regeneration after *PTEN* deletion, although we do not know at present whether this occurs in all RGCs or just in some RGC subtypes.

In the undamaged retina, overexpression of ATF3 did not activate the mTOR pathway ([Fig. 6](#fig6){ref-type="fig"}D) and vice versa, mTOR activation did not induce ATF3 expression. This contradicts previous studies demonstrating the upregulation of ATF3 after *PTEN* deletion in lung epithelial and prostatic epithelial cells.[@bib58]^,^[@bib59] This is likely however because of the differences between epithelial cells and RGCs and indeed, *PTEN* deletion in these cells, unlike in RGCs, led to tumorigenesis. *PTEN* deletion significantly decreased the number of ATF3-positive RGCs after ONC ([Figs. 6](#fig6){ref-type="fig"}A-C). At present, it is not entirely clear why overexpression of ATF3 alone promoted RGC survival but not RGC axon regeneration following ONC, whereas in combination with PTEN deletion, overexpression of ATF3 did not improve RGC survival but stimulated limited RGC axon regeneration. We can hypothesize that other players could be also involved. For example, it has been shown that optic nerve injury triggers rapid upregulation of the stress-induced proteins REDD1 and REDD2 (regulated in development and DNA damage responses 1 and 2, respectively), potent inhibitors of mTOR.[@bib53]^,^[@bib54] REDD2 upregulation and mTOR inhibition led to RGC dendrite pathology causing neuronal dysfunction and subsequent RGC death,[@bib60] whereas suppression of REDD1 expression promoted RGC survival and axon elongation after ONC.[@bib61] Combinatorial action of REDD1/2, PTEN, ATF3, and some other factors may lead to the observed effects. The elucidation of molecular processes involved in neuroprotective mechanisms of ATF3 action in the retina and CNS in general represents an important avenue of further research.
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